Skip to content

EBITDA at other companies

Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$102.98M-38.6%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

$187.9Mebit+
$723.0KDepreciation Depletion & Amortization
=-$187.19M

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s EBITDA?
Erasca, Inc. (ERAS) reported EBITDA of -$187.19M in Q1 2026.
How has Erasca, Inc.'s EBITDA changed year-over-year?
Erasca, Inc.'s EBITDA decreased by 437.8% year-over-year, from -$34.81M to -$187.19M.
What is the long-term trend for Erasca, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Erasca, Inc.'s EBITDA has grown at a 2.7% compound annual growth rate (CAGR), from -$124.05M to -$137.8M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.